Standout Papers

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Car... 2010 2026 2015 2020 623
  1. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival (2010)
    Bernard Escudier, Joaquim Bellmunt et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 27 from Science/Nature 77 standout
Sub-graph 1 of 21

Citing Papers

Mitochondrial transfer mediates endothelial cell engraftment through mitophagy
2024 StandoutNature
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
2 intermediate papers

Works of Vesna Šneller being referenced

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
2010 Standout

Author Peers

Author Last Decade Papers Cites
Vesna Šneller 573 357 100 578 357 12 982
L Pyle 351 231 62 435 293 18 796
J Pény 619 238 435 400 441 14 1.2k
Stéphanie Marion 728 337 351 614 315 7 1.2k
Tania Mariani 573 256 433 483 200 8 981
Heidi Steinfeldt 393 251 47 687 580 10 1.1k
Alexandra Karadimou 445 219 131 340 460 25 917
Jakub Żołnierek 762 437 92 602 425 23 1.1k
Regula Deurloo 202 216 71 307 454 12 902
Mustafa Al-Mubarak 297 390 143 211 731 12 1.1k
Douglas P. Calvin 304 427 107 544 391 12 1.1k

All Works

Loading papers...

Rankless by CCL
2026